11.18.21
Ingredient supplier AIDP has added the Cognilipid portfolio of brands to its Nootropic ingredient portfolio. The phospholipid ingredients contain phosphatidylserine (PS) and phosphatidic acid (PA) in proprietary blends.
CogniPLUS is a proprietary branded complex of phospholipids, including PS and PA with both manufacturing and use patents. It is the subject of several human clinical studies focused on parameters of stress, memory, mood, and PMS symptoms. In clinical trials assessing its efficacy, participants recorded improvements in memory, learning, association, and information gathering scores after 3 months of supplementation, and an improved self-reported quality of life. Participants in the PMS study reported an average decrease of PMS symptoms by 19% over 4 menstrual cycles.
CogniPS and CogniPA, both PS and PA ingredients respectively, are each protected by patents on their solvent-free manufacturing processes, and both are formulated to act synergistically for cognitive support and performance.
For this line of products, AIDP is partnering with the Israel-based Lipogen, which has been manufacturing and innovating with phospholipids since 1991. The company was the first to introduce phosphatidylserine globally, and clinically test soy-lecithin-based PS.
“AIDP is excited to introduce the Cognilipid brand of products into our cognitive health solutions portfolio,” Mark Thurson, president of AIDP, said. “Consumers and our customers are looking for new clinically-supported nootropic solutions as the market continues to expand.”
CogniPLUS is a proprietary branded complex of phospholipids, including PS and PA with both manufacturing and use patents. It is the subject of several human clinical studies focused on parameters of stress, memory, mood, and PMS symptoms. In clinical trials assessing its efficacy, participants recorded improvements in memory, learning, association, and information gathering scores after 3 months of supplementation, and an improved self-reported quality of life. Participants in the PMS study reported an average decrease of PMS symptoms by 19% over 4 menstrual cycles.
CogniPS and CogniPA, both PS and PA ingredients respectively, are each protected by patents on their solvent-free manufacturing processes, and both are formulated to act synergistically for cognitive support and performance.
For this line of products, AIDP is partnering with the Israel-based Lipogen, which has been manufacturing and innovating with phospholipids since 1991. The company was the first to introduce phosphatidylserine globally, and clinically test soy-lecithin-based PS.
“AIDP is excited to introduce the Cognilipid brand of products into our cognitive health solutions portfolio,” Mark Thurson, president of AIDP, said. “Consumers and our customers are looking for new clinically-supported nootropic solutions as the market continues to expand.”
